A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

• Sponsor: Janssen Research & Development, LLC (Industry)
• Overall Status: Terminated
• CT.gov ID: NCT02462473
• Collaborator: (none)
• Enrollment: 9
• Locations: 3
• Arms: 3
• Duration (Months): 8
• Patients Per Site: 3
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL results are not available.

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia; Schizoaffective Disorder	Drug: Aripiprazole; Drug: Olanzapine; Drug: Paliperidone; Drug: Quetiapine; Drug: Risperidone	Phase 2

Detailed Description

This is a naturalistic, open-label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study), pilot clinical utility study with a sequential and parallel cohort design in participants with a diagnosis of schizophrenia or schizoaffective disorder. The study consists of up to 3 Phases: Screening Phase (Screening and first assessment visit should preferably take place on the same day), active assessment phase (12 weeks, An optional 12 week extension phase. Participants will be assigned to Cohort 1, or randomized to Cohort 2 or Cohort 3. Participants in cohorts 2 and 3 who are receiving long acting injectable (LAI) formulations of paliperidone and/or risperidone and complete participation in the active assessment phase) will have the option of continuing into the extension phase. The duration of study participation will be approximately 12 weeks. Participants in the optional extension phase will have an additional 12 weeks of study participation. The primary outcome will be measured by the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit. Participants' safety will be monitored throughout the study.

Study Design

• Study Type: Interventional
• Actual Enrollment: 9 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
• Study Start Date: May 1, 2015
• Actual Primary Completion Date: Jan 1, 2016
• Actual Study Completion Date: Jan 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1 Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.	Drug: Aripiprazole; Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Olanzapine; Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Paliperidone; Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.; Drug: Quetiapine; Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Risperidone; Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
Experimental: Cohort 2 Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.	Drug: Aripiprazole; Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Olanzapine; Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Paliperidone; Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.; Drug: Quetiapine; Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Risperidone; Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
Experimental: Cohort 3 Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.	Drug: Aripiprazole; Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Olanzapine; Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Paliperidone; Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.; Drug: Quetiapine; Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.; Drug: Risperidone; Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.

Outcome Measures

Primary Outcome Measures

1. Number of Participants With Medication Treatment Modifications (MTM) [Up to Week 12]

   Information on MTMs derived from data collected in the clinical assessment of the schizophrenia patient (CASP) questionnaire. The CASP captured changes in medications, changes in psychosocial treatments, visit frequency, and the need for any acute interventions. The CASP comprised of 3 sections covering several parameters. The CASP captured changes in treatment options which was used to compute MTM, as well as factors in clinical decision making and the influence of antipsychotic medication plasma levels (AMPL), when they were available, on clinical decision making.

Secondary Outcome Measures

1. Clinical Global Impression-Severity (CGI-S) Score at Week 0 and 12 [Week 0, Week 12]

   Clinical Global Impression-Severity (CGI-S) rating scale used to rate the severity of a participant's overall clinical condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.

2. Dimensions of Psychosis Symptom Severity Scale (DPSS) Total Score at Week 0 and 12 [Week 0, Week 12]

   The DPSS is a clinician-rated scale used to rate 8 domains commonly seen in patients with psychotic disorders. Each domain was rated on a 5-point scale (0 to 4) with anchored description of endpoints. Total score was computed by summing the scores of individual items (range of 0-32). Higher scores represent more severe condition. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.

3. Antipsychotic Medication Plasma Levels (AMPL) During the Active Assessment Phase at Week 12 [Week 12]

   AMPL of the individual participant during the active assessment phase was reported.

4. Number of Participants With Factors Considered in Clinical Decision as Assessed by Clinical Assessment of the Schizophrenia Patient (CASP) [Up to Week 12]

   The CASP and data on concomitant medications and psychosocial treatments were used to evaluate the impact of AMPL results on other aspects of clinical decision making.

5. Clinician's Rating Scale of Adherence (CRS) Score at Week 0 and 12 [Week 0, Week 12]

   The CRS is an ordinal scale filled by the clinician. The scores range from 1 to 7 that were used to quantify the clinician's assessment of treatment adherence by the patient. Higher scores indicate greater adherence. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.

6. Adherence to Antipsychotic Medication as Assessed by Brief Adherence Rating Scale (BARS) at Week 0 and 12 [Week 0, Week 12]

   The BARS is a 4-item scale that includes 3 questions and an overall visual analog rating scale that assesses participant's knowledge about his/her medication. The key measure of adherence is the visual analog scale and assesses the percentage of doses taken by the participants in the past month (0 percent [%] - 100%). The 3 questions include: number of prescribed doses per day, number of days in the past month when the participant did not take the prescribed doses, and the number of days in the past month when the participant took less than the prescribed dose. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.

7. Patient Satisfaction Survey (PSS) Total Score at Week 0 and 12 [Week 0, Week 12]

   The PSS is a brief scale designed to capture a psychiatric patient's satisfaction with a clinician. The scale covers 6 domains: Trust (3 items), Communication (3 items), Exploration of Ideas/Options (2 items), Body Language (2 items), Active Listening (4 items), and Miscellaneous Items (6 items). Out of the 20 items, the first 19 are scored on a 5-point Likert Scale (1=strongly disagree, 2=disagree, 3=satisfactory, 4=agree, 5=strongly agree). The last question (6f) is a free-response question asking for input on how the clinician might improve. Sum of scores of individual items give a total score (range 9-95). Higher scores indicate greater degree of satisfaction. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Participant has a diagnosis of schizophrenia (Code 295.90) or schizoaffective disorder (Code 295.70) according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM 5), based on history and clinical assessment by the investigator

• Participant has current active medication management issues and has experienced a medication treatment modification within the 6 weeks prior to Screening

• Participant is currently taking one or more of the following antipsychotic medications for at least 1 week for oral antipsychotics and at least 1 injection cycle for long-acting injectable (LAI) antipsychotics. In addition, the treating clinician plans to continue the antipsychotic medication(s) for at least 4 weeks subsequent to the Screening visit. Participant may be taking more than one formulation of a particular medication (such as oral and LAI) at or above the minimum dose specified in protocol. Qualifying formulations of the antipsychotic medications are: Aripiprazole (oral formulation only), Olanzapine (oral formulation only), Paliperidone (oral and/or LAI formulations), Quetiapine (oral formulation only), and Risperidone (oral and/or LAI formulations)

• Participant has had no clinically significant suicidal behavior or ideation during the week prior to Screening, according to the investigator's judgment

• Participant is generally healthy and has no clinically significant or unstable medical problems as determined by the investigator, except for the indication for which the antipsychotic treatment is being prescribed. This determination must be recorded in the participant's source documents and initialed by the investigator

Exclusion Criteria:

• Participant has been attending the outpatient psychiatric clinic for more than 12 months since the last psychiatric hospitalization

• During Screening, participant has active alcohol or substance use disorder (except tobacco) of moderate or severe severity according to DSM 5 criteria

• Participant has a history of or currently has a clinically significant (particularly unstable) medical illness, other than the indication for which the participant is taking antipsychotic therapy, that the investigator considers should exclude the participant or that could interfere with the participant completing the study or with interpretation of the study results. Treated, stable, chronic medical problems are allowed, as long as these conditions do not interfere with the study assessments

• Participant is receiving clozapine

• Participant has donated blood or blood products or had substantial loss of blood (ie, blood loss of approximately more than 450 milliliter (mL) or blood loss that required a blood transfusion) within 1 month of Screening or has the intention to donate blood or blood products during the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1		Torrance	California	United States
2		Kissimmee	Florida	United States
3		Conshohocken	Pennsylvania	United States

Sponsors and Collaborators

• Janssen Research & Development, LLC

Investigators

• Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Janssen Research & Development, LLC
• ClinicalTrials.gov Identifier: NCT02462473
• Other Study ID Numbers: CR106922; CODX0001NAP2002
• First Posted: Jun 4, 2015
• Last Update Posted: Mar 29, 2017
• Last Verified: Feb 1, 2017

• Keywords provided by Janssen Research & Development, LLC: Schizophrenia; Schizoaffective Disorder; Aripiprazole; Olanzapine; Paliperidone; Quetiapine; Risperidone; Liquid Chromatography-Tandem Mass Spectrometry
• Additional relevant MeSH terms: Schizophrenia; Psychotic Disorders; Olanzapine; Risperidone; Aripiprazole; Quetiapine Fumarate; Paliperidone Palmitate

Study Results

Participant Flow

Pre-assignment Detail	The study had a planned enrollment of approximately 155 participants into 3 cohorts. However a total of 9 participants were enrolled and analyzed for efficacy and safety assessments in Cohort 1 and no participants were enrolled into Cohorts 2 or 3 of the study.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Period Title: Overall Study
STARTED	9
COMPLETED	5
NOT COMPLETED	4

Baseline Characteristics

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Overall Participants	9
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	8 88.9%
>=65 years	1 11.1%
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	46.2 (13.15)
Sex: Female, Male (Count of Participants)
Female	2 22.2%
Male	7 77.8%

Outcome Measures

1. Primary Outcome

Title	Number of Participants With Medication Treatment Modifications (MTM)
Description	Information on MTMs derived from data collected in the clinical assessment of the schizophrenia patient (CASP) questionnaire. The CASP captured changes in medications, changes in psychosocial treatments, visit frequency, and the need for any acute interventions. The CASP comprised of 3 sections covering several parameters. The CASP captured changes in treatment options which was used to compute MTM, as well as factors in clinical decision making and the influence of antipsychotic medication plasma levels (AMPL), when they were available, on clinical decision making.
Time Frame	Up to Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this endpoint.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	8
Number [Participants]	4 44.4%

2. Secondary Outcome

Title	Clinical Global Impression-Severity (CGI-S) Score at Week 0 and 12
Description	Clinical Global Impression-Severity (CGI-S) rating scale used to rate the severity of a participant's overall clinical condition on a 7-point scale ranging from 1 (not ill) to 7 (extremely severe). Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time Frame	Week 0, Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. One participant (Participant 4) was not analyzed at Week 12 due to discontinuation caused by death.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	9
Participant 1 (Week 0)	4
Participant 1 (Week 12)	3
Participant 2 (Week 0)	4
Participant 2 (Week 12)	3
Participant 3 (Week 0)	4
Participant 3 (Week 12)	4
Participant 4 (Week 0)	5
Participant 5 (Week 0)	3
Participant 5 (Week 12)	3
Participant 6 (Week 0)	3
Participant 6 (Week 12)	3
Participant 7 (Week 0)	3
Participant 7 (Week 12)	4
Participant 8 (Week 0)	4
Participant 8 (Week 12)	3
Participant 9 (Week 0)	3
Participant 9 (Week 12)	3

3. Secondary Outcome

Title	Dimensions of Psychosis Symptom Severity Scale (DPSS) Total Score at Week 0 and 12
Description	The DPSS is a clinician-rated scale used to rate 8 domains commonly seen in patients with psychotic disorders. Each domain was rated on a 5-point scale (0 to 4) with anchored description of endpoints. Total score was computed by summing the scores of individual items (range of 0-32). Higher scores represent more severe condition. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time Frame	Week 0, Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. One participant (Participant 4) was not analyzed at Week 12 due to discontinuation caused by death.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	9
Participant 1 (Week 0)	12
Participant 1 (Week 12)	4
Participant 2 (Week 0)	8
Participant 2 (Week 12)	2
Participant 3 (Week 0)	8
Participant 3 (Week 12)	8
Participant 4 (Week 0)	14
Participant 5 (Week 0)	9
Participant 5 (Week 12)	4
Participant 6 (Week 0)	7
Participant 6 (Week 12)	4
Participant 7 (Week 0)	5
Participant 7 (Week 12)	8
Participant 8 (Week 0)	4
Participant 8 (Week 12)	4
Participant 9 (Week 0)	4
Participant 9 (Week 12)	6

4. Secondary Outcome

Title	Antipsychotic Medication Plasma Levels (AMPL) During the Active Assessment Phase at Week 12
Description	AMPL of the individual participant during the active assessment phase was reported.
Time Frame	Week 12

Outcome Measure Data

Analysis Population Description

AMPL analysis set included all enrolled participants who had AMPL data for at least 1 visit. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this endpoint.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	8
Participant 1- ARIPIPRAZOLE	596.00
Participant 1- DEHYDROARIPIPRAZOLE	139.00
Participant 2- OLANZAPINE	27.30
Participant 2- PALIPERIDONE	45.10
Participant 3- 7-OH QUETIAPINE	43.10
Participant 3-NORQUETIAPINE	660.00
Participant 3-QUETIAPINE	280.00
Participant 3-QUETIAPINE SULFOXIDE	660.00
Participant 5-7-OH QUETIAPINE	7.72
Participant 5-NORQUETIAPINE	153.00
Participant 5-QUETIAPINE	50.30
Participant 5-QUETIAPINE SULFOXIDE	321.00
Participant 6-ARIPIPRAZOLE	464.00
Participant 6-DEHYDROARIPIPRAZOLE	112.00
Participant 7-PALIPERIDONE	31.00
Participant 7-RISPERIDONE	26.20
Participant 8-ARIPIPRAZOLE	168.00
Participant 8-DEHYDROARIPIPRAZOLE	33.00
Participant 9- 7-OH QUETIAPINE	0.200
Participant 9- NORQUETIAPINE	2.00
Participant 9- PALIPERIDONE	0.100
Participant 9- QUETIAPINE	2.00
Participant 9- QUETIAPINE SULFOXIDE	2.00
Participant 9- RISPERIDONE	0.100

5. Secondary Outcome

Title	Number of Participants With Factors Considered in Clinical Decision as Assessed by Clinical Assessment of the Schizophrenia Patient (CASP)
Description	The CASP and data on concomitant medications and psychosocial treatments were used to evaluate the impact of AMPL results on other aspects of clinical decision making.
Time Frame	Up to Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this endpoint.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	6
Side Effects Of Medication	3 33.3%
Attitude Toward Treatment	2 22.2%
Report of Increased Symptoms	4 44.4%
Report of Decrease in Symptoms	3 33.3%
Patient Still Symptomatic	1 11.1%
Patient Ideation	1 11.1%

6. Secondary Outcome

Title	Clinician's Rating Scale of Adherence (CRS) Score at Week 0 and 12
Description	The CRS is an ordinal scale filled by the clinician. The scores range from 1 to 7 that were used to quantify the clinician's assessment of treatment adherence by the patient. Higher scores indicate greater adherence. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time Frame	Week 0, Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. One participant (Participant 4) was not analyzed at Week 12 due to discontinuation caused by death.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	9
Participant 1 (Week 0)	7
Participant 1 (Week 12)	7
Participant 2 (Week 0)	7
Participant 2 (Week 12)	7
Participant 3 (Week 0)	7
Participant 3 (Week 12)	7
Participant 4 (Week 0)	7
Participant 5 (Week 0)	7
Participant 5 (Week 12)	7
Participant 6 (Week 0)	7
Participant 6 (Week 12)	7
Participant 7 (Week 0)	7
Participant 7 (Week 12)	7
Participant 8 (Week 0)	7
Participant 8 (Week 12)	7
Participant 9 (Week 0)	7
Participant 9 (Week 12)	7

7. Secondary Outcome

Title	Adherence to Antipsychotic Medication as Assessed by Brief Adherence Rating Scale (BARS) at Week 0 and 12
Description	The BARS is a 4-item scale that includes 3 questions and an overall visual analog rating scale that assesses participant's knowledge about his/her medication. The key measure of adherence is the visual analog scale and assesses the percentage of doses taken by the participants in the past month (0 percent [%] - 100%). The 3 questions include: number of prescribed doses per day, number of days in the past month when the participant did not take the prescribed doses, and the number of days in the past month when the participant took less than the prescribed dose. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time Frame	Week 0, Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. One participant (Participant 4) was not analyzed at Week 12 due to discontinuation caused by death.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	9
Participant 1 (Week 0)	100
Participant 1 (Week 12)	100
Participant 2 (Week 0)	100
Participant 2 (Week 12)	100
Participant 3 (Week 0)	100
Participant 3 (Week 12)	100
Participant 4 (Week 0)	97
Participant 5 (Week 0)	93
Participant 5 (Week 12)	90
Participant 6 (Week 0)	90
Participant 6 (Week 12)	96
Participant 7 (Week 0)	90
Participant 7 (Week 12)	95
Participant 8 (Week 0)	100
Participant 8 (Week 12)	100
Participant 9 (Week 0)	100
Participant 9 (Week 12)	100

8. Secondary Outcome

Title	Patient Satisfaction Survey (PSS) Total Score at Week 0 and 12
Description	The PSS is a brief scale designed to capture a psychiatric patient's satisfaction with a clinician. The scale covers 6 domains: Trust (3 items), Communication (3 items), Exploration of Ideas/Options (2 items), Body Language (2 items), Active Listening (4 items), and Miscellaneous Items (6 items). Out of the 20 items, the first 19 are scored on a 5-point Likert Scale (1=strongly disagree, 2=disagree, 3=satisfactory, 4=agree, 5=strongly agree). The last question (6f) is a free-response question asking for input on how the clinician might improve. Sum of scores of individual items give a total score (range 9-95). Higher scores indicate greater degree of satisfaction. Due to early study termination collected data was not summarized. Hence, individual data for each participant was reported.
Time Frame	Week 0, Week 12

Outcome Measure Data

Analysis Population Description

All enrolled participants who had a baseline CASP evaluation were included in the efficacy analysis set. One participant (Participant 4) was not analyzed at Week 12 due to discontinuation caused by death.

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
Measure Participants	9
Participant 1 (Week 0)	76
Participant 1 (Week 12)	76
Participant 2 (Week 0)	52
Participant 2 (Week 12)	57
Participant 3 (Week 0)	57
Participant 3 (Week 12)	57
Participant 4 (Week 0)	48
Participant 5 (Week 0)	66
Participant 5 (Week 12)	64
Participant 6 (Week 0)	76
Participant 6 (Week 12)	76
Participant 7 (Week 0)	76
Participant 7 (Week 12)	72
Participant 8 (Week 0)	63
Participant 8 (Week 12)	72
Participant 9 (Week 0)	71
Participant 9 (Week 12)	76

Adverse Events

Arm/Group Title	Cohort 1
Arm/Group Description	Participants received treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks.
All Cause Mortality
	Cohort 1
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Cohort 1
	Affected / at Risk (%)	# Events
Total	1/9 (11.1%)
General disorders
Death	1/9 (11.1%)
Other (Not Including Serious) Adverse Events
	Cohort 1
	Affected / at Risk (%)	# Events
Total	4/9 (44.4%)
Ear and labyrinth disorders
External ear inflammation	1/9 (11.1%)
Infections and infestations
Pharyngitis	1/9 (11.1%)
Psychiatric disorders
Anxiety	1/9 (11.1%)
Depression	1/9 (11.1%)
Restlessness	1/9 (11.1%)
Skin and subcutaneous tissue disorders
Miliaria	1/9 (11.1%)

Limitations/Caveats

Due to poor enrollment, the study was terminated early by the sponsor after enrolling only 9 participants in Cohort 1 and no participants were enrolled in Cohorts 2 and 3.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days.